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enrolled a total of 1,019 patients with nosocomial pneumonia, including 160 with identified MRSA and 91 with VAP-MRSA.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
The validity of the estimates was ensured by the use of clinical trials.
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
The evidence was derived from a single study, which was a meta-analysis of two trials.
Methods of combining primary studies
A meta-analysis was carried out to pool the primary estimates.
Investigation of differences between primary studies
Results of the review
The cure rate for all patients with nosocomial pneumonia was 59% with LIN and 35.5% with VAN. For patients with VAP-MRSA, the cure rate was 62.2% with LIN and 21.2% with VAN (these values were used in the decision model). All these differences were statistically significant.
Measure of benefits used in the economic analysis
The summary benefit measure used was the cure rate. This was derived directly from the effectiveness analysis.
Direct costs
The perspective adopted in the study was not stated, but it might have been that of the Brazilian health system. The cost analysis included the costs of LIN, VAN (either brand-name or generic), discarded syringes with needle, sterile water for injection, saline solution for infusion, the device for infusion and the infusion pump. The authors stated that the cost of in-hospital stay was not considered because length of stay was equivalent between the groups. The unit costs were presented separately from the quantities of resources used. The list of materials (with prices) used for the administration of each drug was obtained by interviews with nurse teams from a reference institution in Sao Paulo (Instituto do Coracao do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo). The duration of both treatments was standardised to 11 days, based on a published study. Drug dosages were those presented in the literature and recommended by manufacturers. Discounting was not relevant since the costs were incurred during a short timeframe. The price year was 2004.
